Long-lasting neuroprotective effect of sildenafil against 3,4-methylenedioxymethamphetamine- induced 5-hydroxytryptamine deficits in the rat brain

Journal of Neuroscience Research

Volumn 90, Issue 2, 2012, Pages 518-528

  Puerta, Elena ^a   Barros Miñones, Lucia ^a   Hervias, Isabel ^b   Gomez Rodriguez, Violeta ^a   Orejana, Lourdes ^a   Pizarro, Neus ^c   de la Torre, Rafael ^c,d   Jordán, Joaquín ^e   Aguirre, Norberto ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

^e UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

5 HT; 5 hydroxytryptamine; MDMA; PDE5 inhibitor; Preconditioning; Serotonin; Sildenafil

Indexed keywords

3 NITROTYROSINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; BETA ACTIN; ETHIDIUM; MANGANESE SUPEROXIDE DISMUTASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SEROTONIN; SEROTONIN TRANSPORTER; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DENSITY; DRUG EFFECT; ENZYME ACTIVATION; FLUORESCENCE; FRONTAL CORTEX; HIPPOCAMPUS; HYPERTHERMIA; MALE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; BRAIN; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPROTECTIVE AGENTS; PIPERAZINES; PURINES; RATS; RATS, WISTAR; SEROTONIN; SULFONES; TIME FACTORS;

EID: 83155192220     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22759     Document Type: Article

References (65)

1. Abdul HM, Butterfield DA. 2007. Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-L-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. Free Radic Biol Med 42: 371-384.
2. Andoh T, Chiueh CC, Chock PB. 2003. Cyclic GMP-dependent protein kinase regulates the expression of thioredoxin and thioredoxin peroxidase-1 during hormesis in response to oxidative stress-induced apoptosis. J Biol Chem 278: 885-890.
3. Arthur PG, Lim SC, Meloni BP, Munns SE, Chan A, Knuckey NW. 2004. The protective effect of hypoxic preconditioning on cortical neuronal cultures is associated with increases in the activity of several antioxidant enzymes. Brain Res 1017: 146-154.
4. Bhide NS, Lipton JW, Cunningham JI, Yamamoto BK, Gudelsky GA. 2009. Repeated exposure to MDMA provides neuroprotection against subsequent MDMA-induced serotonin depletion in brain. Brain Res 1286: 32-41.
5. Biezonski DK, Meyer JS. 2010. Effects of 3, 4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity. J Neurochem 112: 951-962.
6. Borrás C, Gambini J, Gómez-Cabrera MC, Sastre J, Pallardó FV, Mann GE, Viña J. 2006. Genistein, a soy isoflavone, up-regulates expression of antioxidant genes: involvement of estrogen receptors, ERK1/2, and NFkappaB. FASEB J 20: 2136-2138.
7. Capela JP, Carmo H, Remião F, Bastos ML, Meisel A, Carvalho F. 2009. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 39: 210-271.
8. Chiueh CC, Andoh T, Chock PB. 2005a. Induction of thioredoxin and mitochondrial survival proteins mediates preconditioning-induced cardioprotection and neuroprotection. Ann N Y Acad Sci 1042: 403-418.
9. Chiueh CC, Andoh T, Chock PB. 2005b. Roles of thioredoxin in nitric oxide-dependent preconditioning-induced tolerance against MPTP neurotoxin. Toxicol Appl Pharmacol 207( Suppl): 96-102.
10. Colado MI, O'shea E, Granados R, Murray TK, Green AR. 1997. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA (ecstasy) and p-choroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol 121: 889-900.
11. Corbin JD, Francis SH. 1999. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 274: 13729-13732.
12. Cuadrado-Tejedor M, Hervias I, Ricobaraza A, Puerta E, Pérez-Roldán JM, García-Barroso C, Franco R, Aguirre N, García-Osta A. 2011. Sildenafil restores cognitive function without affecting Aβ burden in an Alzheimer's disease mouse model. Br J Pharmacol [May 31 E-pub ahead of print
13. Darvesh AS, Yamamoto BK, Gudelsky GA. 2005. Evidence for the involvement of nitric oxide in 3, 4-methylenedioxymethamphetamine-induced serotonin depletion in the rat brain. J Pharmacol Exp Ther 312: 694-701.
14. Das DK. 2004. Thioredoxin regulation of ischemic preconditioning. Antioxid Redox Signal 6: 405-412.
15. de Win MM, Jager G, Booij J, Reneman L, Schilt T, Lavini C, Olabarriaga SD, den Heeten GJ, van den Brink W. 2008. Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain 131: 2936-2945.
16. Ding G, Jiang Q, Li L, Zhang L, Zhang ZG, Ledbetter KA, Panda S, Davarani SP, Athiraman H, Li Q, Ewing JR, Chopp M. 2008. Magnetic resonance imaging investigation of axonal remodeling and angiogenesis after embolic stroke in sildenafil-treated rats. J Cereb Blood Flow Metab 28: 1440-1448.
17. Goñi-Allo B, Ramos M, Hervias I, Lasheras B, Aguirre N. 2006. Studies on striatal neurotoxicity caused by the 3, 4-methylenedioxymethamphetamine/malonate combination: implications for serotonin/dopamine interactions. J Psychopharmacol 20: 245-256.
18. Goñi-Allo B, Puerta E, Hervias I, Di Palma R, Ramos M, Lasheras B, Aguirre N. 2007. Studies on the mechanisms underlying amiloride enhancement of 3, 4-methylenedioxymethamphetamine-induced serotonin depletion in rats. Eur J Pharmacol 562: 198-207.
19. Goñi-Allo B, O'mathùna B, Segura M, Puerta E, Lasheras B, de la Torre R, Aguirre N. 2008a. The relationship between core body temperature and 3, 4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity. Psychopharmacology 197: 263-278.
20. Goñi-Allo B, Puerta E, O'Mathúna B, Hervias I, Lasheras B, de la Torre R, Aguirre N. 2008b. On the role of tyrosine and peripheral metabolism in 3, 4-methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats. Neuropharmacology 54: 885-900.
21. Goñi-Allo B, Puerta E, Ramos M, Lasheras B, Jordan J, Aguirre N. 2008c. Minoxidil prevents 3, 4-methylenedioxymethamphetamine-induced serotonin depletions: role of mitochondrial ATP-sensitive potassium channels, Akt and ERK. J Neurochem 104: 914-925.
22. Gonzalez-Zulueta M, Feldman AB, Klesse LJ, Kalb RG, Dillman JF, Parada LF, Dawson TM, Dawson VL. 2000. Requirement for nitric oxide activation of p21(ras)/extracellular regulated kinase in neuronal ischemic preconditioning. Proc Natl Acad Sci U S A 97: 436-441.
23. Hatzdimitrou G, Mccann UD, Ricaurte GA. 1999. Altered serotonin innervation patterns in the forebrain of monkeys with (+/-)3, 4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 19: 5096-5107.
24. Hervias I, Lasheras B, Aguirre N. 2000. 2-Deoxy-D-glugose prevents and nicotinamide potentiates 3, 4-methylenedioxymethamphetamine-induced serotonin neurotoxicity. J Neurochem 75: 982-990.
25. Huang PL. 2004. Nitric oxide and cerebral ischemic preconditioning. Cell Calcium 36: 323-329.
26. Ischiropoulos H, al-Mehdi AB. 1995. Peroxynitrite-mediated oxidative protein modifications. FEBS Lett 364: 279-282.
27. Jones NM, Bergeron M. 2004. Hypoxia-induced ischemic tolerance in neonatal rat brain involves enhanced ERK1/2 signaling. J Neurochem 89: 157-167.
28. Kim GW, Chan PH. 2002. Involvement of superoxide in excitotoxicity and DNA fragmentation in striatal vulnerability in mice after treatment with the mitochondrial toxin, 3-nitropropionic acid. J Cereb Blood Flow Metab 22: 798-809.
29. 11C]DASB and structural brain imaging study. Brain 133: 1779-1797.
30. Kitagawa K, Matsumoto M, Tagaya M, Hata R, Ueda H, Niinobe M, Handa N, Fukunaga R, Kimura K, Mikoshiba K, Kamada T. 1990. "Ischemic tolerance" phenomenon found in the brain. Brain Res 528: 21-24.
31. Kovács GG, Andó RD, Ádori C, Kirilly E, Benedek A, Palkovits M, Bagdy G. 2007. Single dose of MDMA causes extensive decrement of serotoninergic fiber density without blockage of the fast axonal transport in dark agouti rat brain and spinal cord. Neuropathol Appl Neurobiol 33: 193-203.
32. Lee SY, Andoh T, Murphy DL, Chiueh CC. 2003. 17Beta-estradiol activates ICI 182, 780-sensitive estrogen receptors and cyclic GMP-dependent thioredoxin expression for neuroprotection. FASEB J 17: 947-948.
33. Li Z, Shi K, Guan L, Cao T, Jiang Q, Yang Y, Xu C. 2010. ROS leads to MnSOD upregulation through ERK2 translocation and p53 activation in selenite-induced apoptosis of NB4 cells. FEBS Lett 584: 2291-2297.
34. Mansergh G, Shouse RL, Marks G, Guzman R, Rader M, Buchbinder S, Colfax GN. 2006. Methamphetamine and sildenafil (Viagra) use are linked to unprotected receptive and insertive anal sex, respectively, in a sample of men who have sex with men. Sex Transm Infect 82: 131-134.
35. Mccann UD, Eligulashvili V, Mertl M, Murphy DL, Ricaurte GA. 1999. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3, 4-methylenedioxymethamphetamine (MDMA) users. Psychopharmacology 147: 56-65.
36. 11C]DASB. Neuropsychopharmacology 30: 1741-1750.
37. Mccann UD, Szabo Z, Vranesic M, Palermo M, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA. 2008. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3, 4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology 200: 439-450.
38. Mostafa T. 2008. Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses. J Sex Med 5: 2502-2518.
39. Nagy K, Kis B, Rajapakse NC, Bari F, Busija DW. 2004. Diazoxide preconditioning protects against neuronal cell death by attenuation of oxidative stress upon glutamate stimulation. J Neurosci Res 76: 697-704.
40. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME. 1988. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8: 2788-2803.
41. Orejana L, Barros-Miñones L, Jordán J, Puerta E, Aguirre N. 2011. Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model. Neurobiol Aging [May 3 E-pub ahead of print
42. Paxinos G, Watson C. 1997. The rat brain in stereotaxic coordinates. New York: Academic Press.
43. Perez-Pinzon MA, Xu GP, Dietrich WD, Rosenthal M, Sick TJ. 1997. Rapid preconditioning protects rats against ischemic neuronal damage after 3 but not 7 days of reperfusion following global cerebral ischemia. J Cereb Blood Flow Metab 17: 175-182.
44. Pignataro G, Scorziello A, Di Renzo G, Annunziato L. 2009. Post-ischemic brain damage: effect of ischemic preconditioning and postconditioning and identification of potential candidates for stroke therapy. FEBS J 276: 46-57.
45. Piper BJ, Vu HL, Safain MG, Oliver AJ, Meyer JS. 2006. Repeated adolescent 3, 4-methylenedioxymethamphetamine (MDMA) exposure in rats attenuates the effects of a subsequent challenge with MDMA or a 5-hydroxytryptamine(1A) receptor agonist. J Pharmacol Exp Ther 317: 838-849.
46. Piper BJ, Ali SF, Daniels LG, Meyer JS. 2010. Repeated intermittent methylenedioxymethamphetamine exposure protects against the behavioral and neurotoxic, but not hyperthermic, effects of an MDMA binge in adult rats. Synapse 64: 421-431.
47. Puerta E, Hervias I, Aguirre N. 2009a. On the mechanisms underlying 3, 4-methylenedioxymethamphetamine toxicity: the dilemma of the chicken and the egg. Neuropsychobiology 60: 119-129.
48. Puerta E, Hervias I, Goñi-Allo B, Lasheras B, Jordán J, Aguirre N. 2009b. Phosphodiesterase 5 inhibitors prevent 3, 4-methylenedioxymethamphetamine-induced 5-HT deficits in the rat. J Neurochem 108: 755-766.
49. Puerta E, Hervias I, Barros-Miñones L, Jordan J, Ricobaraza A, Cuadrado-Tejedor M, García-Osta A, Aguirre N. 2010a. Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. Neurobiol Dis 38: 237-245.
50. Puerta E, Hervias I, Goñi-Allo B, Zhang SF, Jordán J, Starkov AA, Aguirre N. 2010b. Methylenedioxymethamphetamine inhibits mitochondrial complex I activity in mice: a possible mechanism underlying neurotoxicity. Br J Pharmacol 160: 233-245.
51. Puerta E, Pastor F, Dvoracek J, de Saavedra MD, Goñi-Allo B, Jordán J, Hervias I, Aguirre N. 2010c. Delayed pre-conditioning by 3-nitropropionic acid prevents 3, 4-methylenedioxymetamphetamine-induced 5-HT deficits. J Neurochem 114: 843-852.
52. Raja SG. 2006. Cardioprotection with sildenafil: implications for clinical practice. Curr Med Chem 13: 3155-3164.
53. Reagan-Shaw S, Nihal M, Ahmad N. 2008. Dose translation from animal to human studies revisited. FASEB J 22: 659-661.
54. Ricaurte GA, DeLanney LE, Wiener SG, Irwin I, Langston JW. 1988. 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3, 4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res 474: 359-363.
55. Schlossmann J, Feil R, Hofmann F. 2003. Signaling through NO and cGMP-dependent protein kinases. Ann Med 35: 21-27.
56. Scorziello A, Santillo M, Adornetto A, Dell'aversano C, Sirabella R, Damiano S, Canzoniero LM, Renzo GF, Annunziato L. 2007. NO-induced neuroprotection in ischemic preconditioning stimulates mitochondrial Mn-SOD activity and expression via Ras/ERK1/2 pathway. J Neurochem 103: 1472-1480.
57. Shamloo M, Rytter A, Wieloch T. 1999. Activation of the extracellular signal-regulated protein kinase cascade in the hippocampal CA1 region in a rat model of global cerebral ischemic preconditioning. Neuroscience 93: 81-88.
58. Shankaran M, Yamamoto BK, Gudelsky GA. 1999. Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3, 4-methylenedioxymethamphetamine. Eur J Pharmacol 385: 103-110.
59. Shankaran M, Yamamoto BK, Gudelsky GA. 2001. Ascorbic acid prevents 3, 4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. Synapse 40: 55-64.
60. Smith KM, Romanelli F. 2005. Recreational use and misuse of phosphodiesterase 5 inhibitors. J Am Pharm Assoc 45: 63-72.
61. Sprague J, Nichols DE. 1995. The monoamine oxidase-B inhibitor l-deprenyl protects against 3, 4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J Pharmacol Exp Ther 273: 667-673.
62. Stenzel-Poore MP, Stevens SL, Xiong Z, Lessov NS, Harrington CA, Mori M, Meller R, Rosenzweig HL, Tobar E, Shaw TE, Chu X, Simon RP. 2003. Effect of ischaemic preconditioning on genomic response to cerebral ischaemia: similarity to neuroprotective strategies in hibernation and hypoxia-tolerant states. Lancet 362: 1028-1037.
63. Teshima Y, Akao M, Li RA, Chong TH, Baumgartner WA, Johnston MV, Marban E. 2003. Mitochondrial ATP-sensitive potassium channel activation protects cerebellar granule neurons from apoptosis induced by oxidative stress. Stroke 34: 1796-1802.
64. Vidavalur R, Penumathsa SV, Zhan L, Thirunavukkarasu M, Maulik N. 2006. Sildenafil induces angiogenic response in human coronary arteriolar endothelial cells through the expression of thioredoxin, hemeoxygenase and vascular endothelial growth factor. Vasc Pharmacol 45: 91-95.
65. Zeynalov E, Shah ZA, Li RC, Doré S. 2009. Heme oxygenase 1 is associated with ischemic preconditioning-induced protection against brain ischemia. Neurobiol Dis 35: 264-269.